The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24‐week, double‐blind, randomized trial
Open accessAbstract
Aims To compare the efficacy and tolerability of the dipeptidyl peptidase‐4 inhibitor, vildagliptin, with the alpha glucosidase inhibitor, acarbose, in drug‐naive patients with Type 2 diabetes. Methods This multi‐centre, randomized, double‐blind, parallel‐arm study compared the efficacy and tolerability of vildagliptin (100 mg daily, given as 50 mg twice daily, n = 441) and acarbose (up to 300 mg daily, given as three equally divided doses, n = 220) during 24‐week treatment in drug‐naive patients with Type 2 diabetes. Results Monotherapy with vildagliptin or acarbose decreased glycated haemoglobin (HbA 1c) (baseline ≈ 8.6%) to a similar extent during 24‐week treatment. The adjusted mean change from baseline to end‐point (AMΔ) in HbA 1c was −1.4 ± 0.1% and −1.3 ± 0.1% in patients receiving vildagliptin and acarbose, respectively, meeting the statistical criterion for non‐inferiority (upper limit of 95% confidence interval for between‐treatment difference ≤ 0.4%). The decrease in fasting plasma glucose was similar with acarbose (−1.5 ± 0.2 mmol/l) and vildagliptin (−1.2 ± 0.1 mmol/l). Body weight did not change in vildagliptin‐treated patients (−0.4 ± 0.1 kg) but decreased in acarbose‐treated patients (−1.7 ± 0.2 kg, P < 0.001 vs. vildagliptin). The proportion of patients experiencing any adverse event (AE) was 35% vs. 51% in patients receiving vildagliptin or acarbose, respectively; gastrointestinal AEs were significantly more frequent with acarbose (25.5%) than vildagliptin (12.3%, P < 0.001). No hypoglycaemia was reported for either group. Conclusions Vildagliptin is effective and well tolerated in patients with Type 2 diabetes, demonstrating similar glycaemic reductions to acarbose, but with better tolerability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461
Nathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., & Zinman, B. (2006) · Diabetologia · doi:10.1007/s00125-006-0316-2 · Cited by 420
Matikainen, N., Mänttäri, S., Schweizer, A., Ulvestad, A., Mills, D., Dunning, B. E., Foley, J. E., & Taskinen, M.-R. (2006) · Diabetologia · doi:10.1007/s00125-006-0340-2 · Cited by 336
Self-citationRosenstock, J., Kim, S. W., Baron, M. A., Camisasca, R. ‐., Cressier, F., Couturier, A., & Dejager, S. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00698.x · Cited by 255
Wolever, T., Chiasson, J.-L., Josse, R., Hunt, J., Palmason, C., Rodger, N., Ross, S., Ryan, E., & Tan, M. (1997) · International Journal of Obesity · doi:10.1038/sj.ijo.0800468 · Cited by 71
Cited by
Ma, R. C. W., & Chan, J. C. N. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12098 · Cited by 827
Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review
Deacon, C. F. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01306.x · Cited by 525
Standards of care for type 2 diabetes in China
Weng, J., Ji, L., Jia, W., Lu, J., Zhou, Z., Zou, D., Zhu, D., Chen, L., Chen, L., Guo, L., et al. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2827 · Cited by 315
Self-citationJoshi, S. R., Standl, E., Tong, N., Shah, P., Kalra, S., & Rathod, R. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1070827 · Cited by 303
Derosa, G., & Maffioli, P. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.04.012 · Cited by 76
Metadata
- Authors
- Pan, C., Yang, W., Barona, J. P., Wang, Y., Niggli, M., Mohideen, P., Wang, Y., & Foley, J. E.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2008-03-13
- Volume
- 25
- Issue
- 4
- Pages
- 435-441
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W2099677425
- Cited by
- 165
- References
- 5
- FWCI
- 12.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24‐week, double‐blind, randomized trial. https://app.cochat.ai/papers/10.1111/j.1464-5491.2008.02391.x
- The paper
- Pan, C., Yang, W., Barona, J. P., Wang, Y., Niggli, M., Mohideen, P., Wang, Y., & Foley, J. E. (2008). Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24‐week, double‐blind, randomized trial. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2008.02391.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.